Vertex Pharmaceuticals (VRTX)

Shares of the pharma company are down 17% in the past 12 months.

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.

Palantir leads all stocks in the S&P 500 with a stunning 160% gain in Trump's first 200 days.

This biotech's innovative approach could pay rich dividends down the road.

Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.

It's the second time this year the stock has slumped significantly in one day, and it might represent another attractive entry point.

These stocks have outperformed broader equities over the past decade and still have room to run.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 12.1% year on year to $2.96 billion. The company expects the full year’s revenue to be around $11.93 billion, close to analysts’ estimates. Its non-GAAP profit of $4.52 per share was 6.3% above analysts’ consensus estimates.

Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Large-cap laggards slid on weak results/guidance, cuts and capital moves—led by The Trade Desk, Fortinet, Super Micro, Gartner and Eli Lilly.

There's no guarantee that any stock will beat the market, but the chances look good for these three.

Even with the S&P 500 near an all-time high, there are plenty of compelling growth, dividend, and value stocks to buy now.

Curious about which S&P500 stocks are generating unusual volume on Thursday? Find out below.

Market volatility could increase in the months ahead, but these stocks should hold up well.

Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below.

Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.

There's more good news than bad news for this big biotech stock.

Vertex Pharmaceuticals (VRTX) offers strong growth, solid profitability, and reasonable valuations, making it a top pick for affordable growth investors.

A weaker-than-expected ISM services report reignited fears of a slowing U.S. economy, dragging major indices into the red.

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company announced its experimental pain drug, VX-993, failed a key mid-stage clinical trial. The company’s experimental non-opioid painkiller, VX-993, failed to achieve a statistically significant pain reduction compared to a placebo in a mid-stage study. The trial involved patients who had undergone bunionectomy surgery. Following the failure, Vertex Pharmaceuticals stated it would stop the development of VX-993 as a standalone treatment for acute pain. This setback in the company's drug pipeline overshadowed its recently reported strong second-quarter financial results. The news also compounded concerns after the company revealed that expanding the approval for another pain medicine, Journavx, also faced regulatory hurdles.

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.